孟替瑞林 | 90243-66-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 孟替瑞林
• 英文名称: (3R,6R)-6-methyl-5-oxothiomorpholin-3-ylcarbonyl-L-histidinyl-L-proline amide
• 英文别名: montirelin；(3R,6R)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-6-methyl-5-oxothiomorpholine-3-carboxamide
• CAS: 90243-66-6
• 化学式: C₁₇H₂₄N₆O₄S
• 分子量: 408.481
• InChiKey: RSHMQGIMHQPMEB-IXOXFDKPSA-N

物化性质

• 沸点：
  994.2±65.0 °C(Predicted)
• 密度：
  1.398±0.06 g/cm3(Predicted)
• 溶解度：
  H2O：≥1mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  176
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  组氨酸脯氨酸酰胺 、 (3R,6R)-6-Methyl-5-oxothiomorpholine-3-carboxylic acid 在 (3R,6R)-6-Methyl-5-oxothiomorpholine-3-carboxylic acid 作用下， 生成 孟替瑞林
  参考文献：
  名称：

  Drugs Fut. 1983, 8, 1007

  摘要：

  DOI：

文献信息

• [EN] THIOSEMICARBAZATES AND USES THEREOF<br/>[FR] THIOSEMICARBAZATES ET LEURS UTILISATIONS
  申请人：FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH

  公开号：WO2020227592A1

  公开（公告）日：2020-11-12

  Thioesters, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides; and a chemoselective and site-specific functionalization protocol of protected thiocarbazates and semithiocarbazates are described. The protocol features the use of Mitsunobu reaction to alkylate specifically the nitrogen atom close to the acylthiol moiety with alcohols to produce protected mono-substituted thiocarbazates that can be stored for months, activated under mild conditions at low temperature using halonium reagents and integrated orthogonally to make substituted semicarbazides that can be used, e.g., as synthons in synthesis of aza-amino acid conjugates, azapeptides and other peptidomimetics. Methods for preparing and using ureases, carbazides, semicarbazides, beta-peptides, azapeptides, and other peptidomimetics and azapeptide conjugates, and uses of ureases, carbazides, semicarbazides, beta-peptides, azapeptides in drug discovery, diagnosis, inhibition, prevention and treatment of diseases are also described.

  巯酯，硫代氨基甲酸酯，硫代氨基甲酸酯，半硫代氨基甲酸酯，肽，氮代氨基酸共轭物和氮代肽；以及一种对受保护的硫代氨基甲酸酯和半硫代氨基甲酸酯进行化学选择性和位点特异性功能化的方法被描述。该方法采用三甲基脲反应特异性烷基化靠近酰硫醇基团的氮原子，使用醇生成可储存数月的受保护的单取代硫代氨基甲酸酯，在低温下使用卤化物试剂轻微条件下激活，并与其他基团正交集成以制备取代半氨基甲酸酰胺，例如，可用作氮代氨基酸共轭物，氮代肽和其他肽类模拟物的合成中间体。还描述了制备和使用尿酶，卡巴酰胺，半氨基甲酸酰胺，β-肽，氮代肽和其他肽类模拟物以及氮代肽共轭物的方法，以及尿酶，卡巴酰胺，半氨基甲酸酰胺，β-肽，氮代肽在药物发现，诊断，抑制，预防和治疗疾病中的用途。
• New piperidinylamino-thieno[2,3-D] pyrimidine compounds
  申请人：Dhanoa S. Dale

  公开号：US20050222175A1

  公开（公告）日：2005-10-06

  The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno [2,3-d]pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as pulmonary arterial hypertension, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia and priapism, anxiety, depression, schizophrenia, neural injury and stroke. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also provided.

  该发明涉及5-HT受体拮抗剂。公开了由式I表示的新型哌啶基氨基噻吩[2,3-d]嘧啶化合物，以及其合成和用途，用于治疗由5-HT受体直接或间接介导的疾病。这些疾病包括中枢神经系统疾病，如肺动脉高压、偏头痛、高血压、胃肠道疾病、再狭窄、哮喘、阻塞性气道疾病、前列腺增生和勃起功能障碍、焦虑、抑郁症、精神分裂症、神经损伤和中风。还提供了制备方法、新型中间体和药用盐。
• [EN] INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN<br/>[FR] COMPOSÉS D'INDOLE ET PROCÉDÉS DE TRAITEMENT DE LA DOULEUR VISCÉRALE
  申请人：NEURAXON INC

  公开号：WO2009062319A1

  公开（公告）日：2009-05-22

  The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D/1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The methods of the invention may further comprise the administration of additional therapeutic agent. The invention also features new compounds of Formula (I), pharmaceutical compositions thereof, and methods of resolving enantiomeric mixtures.

  该发明涉及治疗哺乳动物体内因一氧化氮合酶（NOS）或5-羟色胺受体5HT1D/1B的作用引起的内脏疼痛或疾病的方法，通过向需要治疗的患者施用式(I)的吲哚化合物的治疗有效量，或其药学上可接受的盐或前药。该发明的方法还可以包括额外治疗剂的施用。该发明还涉及式(I)的新化合物、其药物组合物以及解决对映体混合物的方法。
• 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY
  申请人：Annedi Subhash C.

  公开号：US20090131503A1

  公开（公告）日：2009-05-21

  The present invention relates to novel 3,5-substituted indole compounds of Formula (I) having nitric oxide synthase (NOS) inhibitory activity together with inhibitory activity at the norepinephrine transporter (NET), to pharmaceutical and diagnostic compositions containing them, and to their medical use.

  本发明涉及具有一氧化氮合酶（NOS）抑制活性以及对去甲肾上腺素转运蛋白（NET）具有抑制活性的新型3,5-取代吲哚化合物（I）的公式，以及含有它们的药用和诊断组合物，以及它们的医疗用途。
• Benzodioxane and benzodioxolane derivatives and uses thereof
  申请人：Zhou Dahui

  公开号：US20060241172A1

  公开（公告）日：2006-10-26

  Compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R 1 , R 2 , R 3 , R 4 , y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

  提供了化学式I或其药用可接受盐的化合物：其中R1、R2、R3、R4、y、n、m和Ar中的每一个如所定义，并在此处描述的类和亚类中，它们是大脑5-羟色胺受体2C亚型的激动剂或部分激动剂。这些化合物和含有这些化合物的组合物可用于治疗多种中枢神经系统疾病，如精神分裂症。